0 false false false false false false false false false true false false false false false false No description of principal activity 2022-03-09 Sage Accounts Production Advanced 2021 - FRS102_2021 950,500 950,500 950,500 xbrli:pure xbrli:shares iso4217:GBP 13966566 2022-03-09 2023-03-31 13966566 2023-03-31 13966566 bus:Director1 2022-03-09 2023-03-31 13966566 core:WithinOneYear 2023-03-31 13966566 core:ShareCapital 2023-03-31 13966566 core:SharePremium 2023-03-31 13966566 core:RetainedEarningsAccumulatedLosses 2023-03-31 13966566 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-03-31 13966566 core:CostValuation core:Non-currentFinancialInstruments 2023-03-31 13966566 core:Non-currentFinancialInstruments 2023-03-31 13966566 bus:SmallEntities 2022-03-09 2023-03-31 13966566 bus:AuditExemptWithAccountantsReport 2022-03-09 2023-03-31 13966566 bus:FullAccounts 2022-03-09 2023-03-31 13966566 bus:SmallCompaniesRegimeForAccounts 2022-03-09 2023-03-31 13966566 bus:PrivateLimitedCompanyLtd 2022-03-09 2023-03-31
COMPANY REGISTRATION NUMBER: 13966566
KS INVESTMENTS SUSSEX LTD
FILLETED UNAUDITED FINANCIAL STATEMENTS
31 March 2023
KS INVESTMENTS SUSSEX LTD
STATEMENT OF FINANCIAL POSITION
31 March 2023
31 Mar 23
Note
£
£
Fixed assets
Investments
4
950,500
Current assets
Debtors
5
157
Cash at bank and in hand
1,488
-------
1,645
Creditors: amounts falling due within one year
6
1,200
-------
Net current assets
445
----------
Total assets less current liabilities
950,945
----------
Net assets
950,945
----------
Capital and reserves
Called up share capital
200
Share premium account
2,002
Profit and loss account
948,743
----------
Shareholders funds
950,945
----------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the period ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
KS INVESTMENTS SUSSEX LTD
STATEMENT OF FINANCIAL POSITION (continued)
31 March 2023
These financial statements were approved by the board of directors and authorised for issue on 15 November 2023 , and are signed on behalf of the board by:
Mr T M Standing FCA
Director
Company registration number: 13966566
KS INVESTMENTS SUSSEX LTD
NOTES TO THE FINANCIAL STATEMENTS
PERIOD FROM 9 MARCH 2022 TO 31 MARCH 2023
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 168 Church Road, Hove, East Sussex, BN3 2DL.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.
4. Investments
Other investments other than loans
£
Cost
At 9 March 2022
Additions
950,500
----------
At 31 March 2023
950,500
----------
Impairment
At 9 March 2022 and 31 March 2023
----------
Carrying amount
At 31 March 2023
950,500
----------
Investments totalling £950,500 have been made in LLP's, the details are as follows:-
The Rehberg project is an investment of £143,500 in an LLP that has set up planning, construction, renovation, and design services to the Rehberg resort which is a 5 star luxury resort and spa in the Harz mountains operated by Kemplinski hotels.
Nemaura is a Life Sciences investment of £200,000 that delivers a safe means of using microneedles to deliver drugs below the surface of the skin.
Cerenet is an investment of £282,000 into an LLP providing tax relief for Research and Development expenditure.
Zolfenac LLP has been established to develop the commercial potential of the patches with molecules to Patents. The Patent rights will be licenced from the Nemaura Group. The investment is £325,000.
The Directors consider that the carrying value of these investments is a fair reflection of their values.
5. Debtors
31 Mar 23
£
Prepayments
157
----
6. Creditors: amounts falling due within one year
31 Mar 23
£
Accruals
1,200
-------